PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33224867-7	2020	LXRs" agonist GW3965 enhanced the inhibitory action of LXR-alpha on the proliferation and metastasis of prostate cancer cells.	GW 3965	14-20	nuclear receptor subfamily 1 group H member 3	Homo sapiens	55-64	
33503887-6	2021	GW7647 (a peroxisome proliferator activated receptor alpha (PPARalpha) agonist) and GW3965 (a dual agonist for LXRalpha and beta) significantly caused PTX3 induction in the fibroblast cells.	GW 3965	84-90	nuclear receptor subfamily 1 group H member 3	Homo sapiens	111-128	
33310663-6	2021	Luciferase assays and siRNA transfection showed that LXRalpha increased the transcription of CYP4F11 and LXRalpha agonist GW3965 could induce the expression of CYP4F11 by activating the LXRalpha-CYP4F11 pathway.	GW 3965	122-128	nuclear receptor subfamily 1 group H member 3	Homo sapiens	53-61	
33310663-6	2021	Luciferase assays and siRNA transfection showed that LXRalpha increased the transcription of CYP4F11 and LXRalpha agonist GW3965 could induce the expression of CYP4F11 by activating the LXRalpha-CYP4F11 pathway.	GW 3965	122-128	nuclear receptor subfamily 1 group H member 3	Homo sapiens	105-113	
33310663-6	2021	Luciferase assays and siRNA transfection showed that LXRalpha increased the transcription of CYP4F11 and LXRalpha agonist GW3965 could induce the expression of CYP4F11 by activating the LXRalpha-CYP4F11 pathway.	GW 3965	122-128	nuclear receptor subfamily 1 group H member 3	Homo sapiens	105-113	
33224867-10	2020	In addition, we indicated that the combination of Afatinib and GW3965 simultaneously increased and activated LXR-alpha, which led to an increase of tumor suppressors, and eventually inhibited tumor progression.	GW 3965	63-69	nuclear receptor subfamily 1 group H member 3	Homo sapiens	109-118	
26669941-7	2016	Activation of LXR-alpha by agonist GW3965 inhibited both primary and TNF-alpha-induced S1PR2 expression.	GW 3965	35-41	nuclear receptor subfamily 1 group H member 3	Homo sapiens	14-23	
32754282-16	2020	In this context, we combined an agonist GW3965 of liver X receptor alpha (LXRalpha), which functioned as a transcription activator of miRNA-378a, and its activation re-sensitized sorafenib-resistant cells to sorafenib treatment in vitro and in vivo.	GW 3965	40-46	nuclear receptor subfamily 1 group H member 3	Homo sapiens	74-82	
30831268-9	2019	The transcriptional regulation by LXRalpha was further supported showing enhanced mRNA expression of PDZK1 in HepG2 cells treated with the selective LXRalpha-agonist GW3965, while treatment with TO 901317 reduced the protein amount of PDZK1.	GW 3965	166-172	nuclear receptor subfamily 1 group H member 3	Homo sapiens	34-42	
30831268-9	2019	The transcriptional regulation by LXRalpha was further supported showing enhanced mRNA expression of PDZK1 in HepG2 cells treated with the selective LXRalpha-agonist GW3965, while treatment with TO 901317 reduced the protein amount of PDZK1.	GW 3965	166-172	nuclear receptor subfamily 1 group H member 3	Homo sapiens	149-157	
25557254-6	2015	Second, hypoxic conditions or treatment with the LXRalpha agonist GW3965 significantly induced the expression of MCP-1, which was completely blocked by treatment with 22-S-HC or infection by shLXRalpha lentivirus in the primary hepatocytes.	GW 3965	66-72	nuclear receptor subfamily 1 group H member 3	Homo sapiens	49-57	
25557254-7	2015	Third, over-expression of LXRalpha or GW3965 treatment increased MCP-1 promoter activity by increasing the binding of hypoxia-inducible factor-1alpha to the hypoxia response elements, together with LXRalpha.	GW 3965	38-44	nuclear receptor subfamily 1 group H member 3	Homo sapiens	198-206	
34124002-5	2021	In this study, we report the development of GW3965-PEG5-VH032 (3), a PROTAC capable of effectively degrading LXRbeta protein.	GW 3965	44-50	nuclear receptor subfamily 1 group H member 3	Homo sapiens	109-116